Please login to the form below

Not currently logged in
Email:
Password:

certolizumab pegol

This page shows the latest certolizumab pegol news and features for those working in and with pharma, biotech and healthcare.

NICE approves UCB Pharma’s Cimzia

NICE approves UCB Pharma’s Cimzia

The draft guidance states that Cimzia (certolizumab pegol) can be used on its own or in combination with methotrexate when other drugs have not worked or are not suitable to treat ... We hope that adding certolizumab pegol to this list will mean that

Latest news

More from news
Approximately 2 fully matching, plus 21 partially matching documents found.

Latest Intelligence

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    107. UCB/ Dermira. Licence ††. Cimzia (certolizumab pegol) - drug repurposing (p2 for psoriasis).

  • VIDEO interview: Neil Weir, UCB VIDEO interview: Neil Weir, UCB

    For UCB, this notion is especially important considering its focus on severe diseases, including the recent launches of Cimzia (certolizumab pegol) for rheumatoid arthritis and Crohn's disease; Vimpat (lacosamide) for

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics